Tectonic Therapeutic Inc. (TECX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case
Tectonic Therapeutic offers a validated, severity-enriched trial design for TX45 in CpcPH-HFpEF, with external support from Merck's CADENCE results. Phase 1b TX45 data show promising hemodynamic effects, and the company's cash runway extends through Q1 2029, reducing near-term financing risk. TX2100, a mechanistically distinct candidate for HHT, further validates the GEODe platform, with Phase 1a results expected by Q3 2026.
Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2
Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF, a large underserved market. TX45's engineered Fc-relaxin fusion overcomes prior failures by extending half-life, enabling durable hemodynamic improvements in the CpcPH subgroup per robust phase 1b data. With a $253.8M cash balance, TECX is funded for phase 2; positive topline data in 2026 could unlock a $0.6B–$1.8B U.S. peak sales opportunity.
Tectonic Therapeutic, Inc. $TECX Shares Sold by Ally Bridge Group NY LLC
Ally Bridge Group NY LLC lowered its stake in shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) by 15.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 138,595 shares of the company's stock after selling 25,088 shares during the quarter. Tectonic Therapeutic accounts
Tectonic Therapeutic Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 2 | $61.82 | $41.92 | -$19.9 | -32.19% |
| PN Peter Nicholson First Bancorp Inc. /ME/ | 8 | $275.04 | $168.48 | -$106.56 | -38.74% |
| NA Nizar Araji National Bank Of Canada /FI/ | 6 | $206.28 | $127.8 | -$78.48 | -38.05% |
 John H. Burbank III Passport Capital LLC | 607,788 | $12.68M | $12.87M | $191,027.77 | 1.51% |
| CD Charlie Durham Sterling Capital Management LLC | 176 | $2,761.5 | $3,688.96 | $927.46 | 33.59% |
Tectonic Therapeutic Inc. (TECX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tectonic Therapeutic Inc. ever had a stock split?
Tectonic Therapeutic Inc. Profile
| Biotechnology Industry | Healthcare Sector | Alise S. Reicin CEO | NASDAQ (NMS) Exchange | 878972108 CUSIP |
| US Country | 60 Employees | - Last Dividend | 21 Jun 2024 Last Split | - IPO Date |
Overview
Tectonic Therapeutic, Inc. is a forefront entity in the biotechnology domain, with its operational focus squarely on the clinical stage of developing therapeutic proteins and antibodies. These advancements are specifically aimed at modulating the activity of G-protein coupled receptors (GPCRs), which are critical to numerous physiological processes and thus present a significant target for therapeutic intervention. The company is well-rooted in Watertown, Massachusetts, showcasing its strategic commitment to leveraging its proprietary GEODe technology platform. This platform underpins the company's efforts in the discovery and development of GPCR-targeted biologic medicines, holding promise for novel treatments in a range of disease areas.
Products and Services
-
RXFP1 Agonist:
This pipeline product of Tectonic Therapeutic, Inc. is currently undergoing phase 1a and 1b clinical trials. It is targeted at treating heart failure with preserved ejection fraction, a condition where the heart muscle contracts normally but the ventricles do not fill with blood properly. The development of this RXFP1 agonist demonstrates the company's commitment to addressing critical cardiovascular conditions through innovative GPCR-targeted therapies.
-
GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia:
The company is also working on a GPCR antagonist aimed at treating hereditary hemorrhagic telangiectasia, a genetic disorder that results in abnormal blood vessel formation. This therapeutic approach exhibits the company’s broader aim of exploring GPCR-targeted therapies for genetic diseases where angiogenesis plays a key role.
-
Bi-functional GPCR Modulator for Fibrosis:
Tectonic Therapeutic's pipeline includes a bi-functional GPCR modulator intended for the treatment of fibrosis. This points to the company's focus on fibrotic diseases, which involve the thickening and scarring of connective tissue, usually as a result of injury, and represent a significant area of unmet medical need.
-
GPCR Modulators:
Aside from the specific products detailed above, the company is continuously working on the discovery and development of various GPCR modulators. These modulators represent a broad category of potential therapeutic agents that can target a wide array of diseases by regulating the activity of GPCR proteins, illustrating Tectonic Therapeutic’s dedication to pioneering in the field of GPCR biology.
Contact Information
